You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

T-cell/CD3 engager

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Malignant Glioma, Glioblastoma Trial in Durham (hEGFRvIII-CD3 (BRiTE), Activated Cell Therapy)

Not yet recruiting
  • Malignant Glioma
  • Glioblastoma
  • hEGFRvIII-CD3 (BRiTE)
  • Activated Cell Therapy
  • Durham, North Carolina
    Duke University Medical Center
Jun 24, 2022

Recurrent Anaplastic Large Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Classic Hodgkin Lymphoma Trial in

Recruiting
  • Recurrent Anaplastic Large Cell Lymphoma
  • +9 more
  • Anti-CD30/CD16A Monoclonal Antibody AFM13
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 9, 2022

Advanced Malignancies Trial in Beijing (1A46 Drug Substance)

Not yet recruiting
  • Advanced Malignancies
  • 1A46 Drug Substance
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Aug 4, 2023

Relapsed/Refractory AML Trial in United States (CLN-049)

Recruiting
  • Relapsed/Refractory AML
  • Tampa, Florida
  • +3 more
Dec 2, 2021

Myelodysplastic Syndrome (MDS) Trial in United States (AMV564 14-Day CIV)

Completed
  • Myelodysplastic Syndrome (MDS)
  • AMV564 14-Day CIV
  • Duarte, California
  • +4 more
Oct 11, 2021

Relapsed or Refractory Hodgkin Lymphoma, Peripheral T Cell Lymphoma Trial (AFM13, AB-101, Cyclophosphamide)

Not yet recruiting
  • Relapsed or Refractory Hodgkin Lymphoma
  • Peripheral T Cell Lymphoma
  • (no location specified)
May 30, 2023

Cutaneous Melanoma, Uveal Melanoma, Mucosal Melanoma Trial in Worldwide (RO7293583, Tocilizumab, Obinutuzumab)

Completed
  • Cutaneous Melanoma
  • +2 more
  • Boston, Massachusetts
  • +13 more
Sep 30, 2022

Leukemia, Relapsed, Myeloid Trial in Netherlands, Switzerland (MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123

Recruiting
  • Leukemia
  • +3 more
  • MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70)
  • Amsterdam, Netherlands
  • +4 more
Jan 4, 2023

Pediatric Cancer, Hodgkin Disease, CD30-Positive DLBCL Trial in Milwaukee (anti-CD30 Bispecific Antibody-armed

Not yet recruiting
  • Pediatric Cancer
  • +11 more
  • anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC)
  • Milwaukee, Wisconsin
    Children's Wisconsin
Sep 14, 2022

Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse Trial in Xuzhou (anti Tim-3/CD123 CAR-T cell therapy)

Recruiting
  • Acute Myeloid Leukemia Refractory
  • Acute Myeloid Leukemia, in Relapse
  • anti Tim-3/CD123 CAR-T cell therapy
  • Xuzhou, Jiangsu, China
    Kailin Xu
Nov 4, 2023

Non Hodgkin's Lymphoma Trial in Beijing (TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T),

Not yet recruiting
  • Non Hodgkin's Lymphoma
  • TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T)
  • +2 more
  • Beijing, China
  • +2 more
Aug 23, 2023

Non-Hodgkin's Lymphoma (Disorder), Acute Lymphoid Leukemia, Disease (Disorder) Trial in Louisville, Houston (1A46 Injection)

Recruiting
  • Non-Hodgkin's Lymphoma (Disorder)
  • Acute Lymphoid Leukemia, Disease (Disorder)
  • 1A46 Injection
  • Louisville, Kentucky
  • +1 more
Aug 1, 2022

B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma, Diffuse Large B Cell Lymphoma Trial in Beijing (CD19/CD22-bispecific CAR-T

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • +2 more
  • CD19/CD22-bispecific CAR-T cells
  • Beijing, Beijing, China
    Liang Wang
Oct 7, 2023

T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma Trial (CD7-CART01)

Not yet recruiting
  • T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
  • CD7-CART01
  • (no location specified)
Sep 26, 2023

Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Juvenile Myelomonocytic Leukemia Trial (Miltenyi CliniMACS Prodigy ®

Not yet recruiting
  • Acute Lymphoblastic Leukemia
  • +6 more
  • Miltenyi CliniMACS Prodigy ® system
  • (no location specified)
Mar 23, 2023

Small Cell Lung Carcinoma, Neuroendocrine Tumors Trial (BI 764532)

Not yet recruiting
  • Small Cell Lung Carcinoma
  • Neuroendocrine Neoplasms
  • BI 764532
  • (no location specified)
May 22, 2023

Extranodal NK T Cell Lymphoma, NK-Cell Leukemia Trial in Xuzhou (Anti-CD56 CAR T)

Recruiting
  • Extranodal NK T Cell Lymphoma
  • NK-Cell Leukemia
  • Anti-CD56 CAR T
  • Xuzhou, Jiangsu, China
    The Affiliated Hospital of Xuzhou Medical University
Jul 10, 2023

Resistance to GNC-038 in Relapsed and Refractory Diffuse Large

Recruiting
  • Diffuse Large B Cell Lymphoma
    • Shanghai, Shanghai, China
      Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
    Apr 17, 2022

    High-risk MDS, Acute Myelogenous Leukemia, Systemic Mastocytosis Trial in Minneapolis, Madison (GTB-3550 TriKE® Phase I,

    Terminated
    • High-risk Myelodysplastic Syndromes
    • +3 more
    • GTB-3550 TriKE® Phase I
    • GTB-3550 TriKE® Phase II
    • Minneapolis, Minnesota
    • +1 more
    Mar 21, 2022

    Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma Trial in Boston (CD79b-19 CAR T cells,

    Not yet recruiting
    • Non-hodgkin Lymphoma
    • +9 more
    • CD79b-19 CAR T cells
    • +2 more
    • Boston, Massachusetts
      Massachusetts General Hospital
    Sep 6, 2023

    Peripheral T Cell Lymphoma Trial in China (CAR-T Therapy)

    Not yet recruiting
    • Peripheral T Cell Lymphoma
    • CAR-T Therapy
    • Hefei, Anhui, China
    • +7 more
    Jul 31, 2023

    Interleukins in Periodontal Disease Progression

    Recruiting
    • Periodontitis
    • Gingivitis
    • Flow Cytometric Detection of Regulatory T Cells and Cytokines analysis by ELISA
    • Assiut, Asyut, Egypt
      Department of oral medicine, Periodontology, Oral diagnosis and
    Nov 16, 2023

    DLBCL, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma Trial (biological, procedure, drug,

    Not yet recruiting
    • Diffuse Large B-Cell Lymphoma
    • +6 more
    • Axicabtagene Ciloleucel
    • +10 more
    • (no location specified)
    Jan 13, 2023

    Pancreatic Ductal Adenocarcinoma, NSCLC, Colorectal Cancer Trial (AFNT-211)

    Not yet recruiting
    • Pancreatic Ductal Adenocarcinoma
    • +4 more
    • (no location specified)
    Oct 23, 2023

    Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive Trial in Palo Alto

    Not yet recruiting
    • Multiple Sclerosis
    • +2 more
    • KYV-101 anti-CD19 CAR-T cell therapy
    • Standard lymphodepletion regimen
    • Palo Alto, California
      Stanford Multiple Sclerosis Center
    Nov 13, 2023